Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spheramine in advanced Parkinson's disease
NCT00761436Phase 2Terminated
- Sponsor
- Bayer
- Start
- Feb 2000
- Primary completion
- May 2012
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Spheramine in Parkinson's disease (PD), sponsored by Bayer. Started Feb 2000; status: terminated.
02
Drugs
Spheramine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00761436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761436.